Sugi Predict

Sugi Predict / Compounds / SCHEMBL3960413

SCHEMBL3960413

SCHEMBL3960413

COc1cccc(C)c1S(=O)(=O)Nc1cc(OC2CCNCC2)c2occc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 1/20 0.71
▸ KAT7 O95251 1/20 0.36
▸ KAT6B Q8WYB5 1/20 0.36
▸ KAT6A Q92794 1/20 0.36
▸ KAT5 Q92993 1/20 0.36
▸ KAT8 Q9H7Z6 1/20 0.36
▸ PDE4A P27815 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ NMT1 P30419 5/20 0.35
▸ ALOX12 P18054 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3958865 0.83 HTR6 (1.00) HTR6MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL3956245 0.78 HTR6 (0.78) HTR6MEN1KMT2ASMN1; SMN2IKBKB
SCHEMBL3963801 0.78 HTR6 (0.82) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL13361991 0.77 HTR6 (0.79) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL2966777 0.76 HTR6 (0.72) HTR6MEN1LMNATSHRKMT2A
SCHEMBL3958890 0.76 HTR6 (0.64) HTR6
SCHEMBL3960019 0.73 HTR6 (0.81) HTR6MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL13703577 0.71 HTR6 (0.58) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL13703580 0.71 HTR6 (0.63) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL3324077 0.70 HTR6 (0.76) HTR6MEN1LMNAHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582767-B2 Substituted sulphonamide compound and uses thereof BIOVITRUM AB (PUBL.) (SE) 2009-09-01 — — US disclosed
EP-1896460-B1 BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS BIOVITRUM AB PUBL (SE) 2009-07-22 — — EP disclosed
EP-1896460-A1 BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS Biovitrum AB (publ) (SE) 2008-03-12 — — EP disclosed
US-20060293361-A1 N-[7-(4-piperidinyl)oxy-1-benzofuran-5-yl]-5-hydroxymethyl-2-methoxybenzenesulfonamide; the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, CNS disorders, to achieve reduction of body weight and/or body weight gain PROXIMAGEN NEUROSCIENCE PLC (GB) 2006-12-28 — — US disclosed
WO-2006134150-A1 BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS BIOVITRUM AB (PUBL) (SE) 2006-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293361-A1 N-[7-(4-piperidinyl)oxy-1-benzofuran-5-yl]-5-hydroxymethyl-2-methoxybenzenesulfonamide; the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, CNS disorders, to achieve reduction of body weight and/or body weight gain GPR119, CNR2, SULT1E1 HTR6 598/4885KAT7 1620/4885KAT6B 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.